SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-015848
Filing Date
2023-05-25
Accepted
2023-05-25 16:14:11
Documents
17
Period of Report
2023-05-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20230525_8k.htm   iXBRL 8-K 40264
2 EXHIBIT 3.1 ex_526502.htm EX-3.1 76660
3 EXHIBIT 10.1 ex_526503.htm EX-10.1 29505
4 EXHIBIT 10.2 ex_526504.htm EX-10.2 29327
5 EXHIBIT 99.1 ex_526505.htm EX-99.1 14813
  Complete submission text file 0001437749-23-015848.txt   380801

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA navb-20230522.xsd EX-101.SCH 4035
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20230522_def.xml EX-101.DEF 13890
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20230522_lab.xml EX-101.LAB 18202
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20230522_pre.xml EX-101.PRE 13912
11 EXTRACTED XBRL INSTANCE DOCUMENT navb20230525_8k_htm.xml XML 4382
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 23960648
SIC: 2835 In Vitro & In Vivo Diagnostic Substances